vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and MODIV INDUSTRIAL, INC. (MDV). Click either name above to swap in a different company.

MODIV INDUSTRIAL, INC. is the larger business by last-quarter revenue ($11.1M vs $11.0M, roughly 1.0× C4 Therapeutics, Inc.). MODIV INDUSTRIAL, INC. runs the higher net margin — 11.0% vs -186.0%, a 196.9% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs -5.6%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs -3.8%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

MODIV INDUSTRIAL, INC. is a U.S.-based industrial real estate enterprise focused on acquiring, owning and operating high-quality industrial properties mainly located in key logistics and distribution hubs across North America. It serves tenants from sectors including e-commerce fulfillment, manufacturing and third-party logistics, addressing rising demand for modern supply chain infrastructure.

CCCC vs MDV — Head-to-Head

Bigger by revenue
MDV
MDV
1.0× larger
MDV
$11.1M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+118.4% gap
CCCC
112.8%
-5.6%
MDV
Higher net margin
MDV
MDV
196.9% more per $
MDV
11.0%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
-3.8%
MDV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCCC
CCCC
MDV
MDV
Revenue
$11.0M
$11.1M
Net Profit
$-20.5M
$1.2M
Gross Margin
Operating Margin
-210.1%
45.8%
Net Margin
-186.0%
11.0%
Revenue YoY
112.8%
-5.6%
Net Profit YoY
40.7%
-22.0%
EPS (diluted)
$-0.09
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
MDV
MDV
Q4 25
$11.0M
$11.1M
Q3 25
$11.2M
$11.7M
Q2 25
$6.5M
$11.8M
Q1 25
$7.2M
$11.8M
Q4 24
$5.2M
$11.7M
Q3 24
$15.4M
$11.7M
Q2 24
$12.0M
$11.4M
Q1 24
$3.0M
$12.0M
Net Profit
CCCC
CCCC
MDV
MDV
Q4 25
$-20.5M
$1.2M
Q3 25
$-32.2M
$1.0M
Q2 25
$-26.0M
$-2.0M
Q1 25
$-26.3M
$829.0K
Q4 24
$-34.6M
$1.6M
Q3 24
$-24.7M
$-587.0K
Q2 24
$-17.7M
$1.3M
Q1 24
$-28.4M
$3.7M
Operating Margin
CCCC
CCCC
MDV
MDV
Q4 25
-210.1%
45.8%
Q3 25
-306.4%
41.4%
Q2 25
-441.0%
9.8%
Q1 25
-402.9%
40.2%
Q4 24
-728.4%
45.4%
Q3 24
-183.9%
42.0%
Q2 24
-178.6%
44.6%
Q1 24
-1060.2%
55.6%
Net Margin
CCCC
CCCC
MDV
MDV
Q4 25
-186.0%
11.0%
Q3 25
-286.4%
9.0%
Q2 25
-402.6%
-17.1%
Q1 25
-363.7%
7.0%
Q4 24
-667.8%
13.3%
Q3 24
-160.6%
-5.0%
Q2 24
-147.6%
11.6%
Q1 24
-933.2%
31.1%
EPS (diluted)
CCCC
CCCC
MDV
MDV
Q4 25
$-0.09
$0.02
Q3 25
$-0.44
$0.00
Q2 25
$-0.37
$-0.32
Q1 25
$-0.37
$-0.01
Q4 24
$-0.50
$0.07
Q3 24
$-0.35
$-0.18
Q2 24
$-0.26
$0.03
Q1 24
$-0.41
$0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
MDV
MDV
Cash + ST InvestmentsLiquidity on hand
$74.6M
$14.4M
Total DebtLower is stronger
$261.5M
Stockholders' EquityBook value
$256.6M
$162.7M
Total Assets
$359.1M
$476.5M
Debt / EquityLower = less leverage
1.61×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
MDV
MDV
Q4 25
$74.6M
$14.4M
Q3 25
$58.8M
$8.3M
Q2 25
$78.2M
$5.8M
Q1 25
$51.3M
$6.2M
Q4 24
$55.5M
$11.5M
Q3 24
$59.6M
$6.8M
Q2 24
$73.1M
$18.9M
Q1 24
$89.7M
$18.4M
Total Debt
CCCC
CCCC
MDV
MDV
Q4 25
$261.5M
Q3 25
$279.7M
Q2 25
$279.7M
Q1 25
$279.7M
Q4 24
$279.8M
Q3 24
$279.7M
Q2 24
$279.7M
Q1 24
$279.6M
Stockholders' Equity
CCCC
CCCC
MDV
MDV
Q4 25
$256.6M
$162.7M
Q3 25
$154.4M
$164.8M
Q2 25
$174.1M
$165.6M
Q1 25
$195.1M
$171.1M
Q4 24
$216.0M
$190.1M
Q3 24
$242.7M
$186.3M
Q2 24
$247.1M
$187.0M
Q1 24
$258.3M
$188.0M
Total Assets
CCCC
CCCC
MDV
MDV
Q4 25
$359.1M
$476.5M
Q3 25
$265.5M
$499.6M
Q2 25
$296.5M
$498.9M
Q1 25
$319.5M
$506.8M
Q4 24
$349.6M
$507.8M
Q3 24
$376.1M
$507.4M
Q2 24
$381.1M
$519.5M
Q1 24
$398.4M
$522.5M
Debt / Equity
CCCC
CCCC
MDV
MDV
Q4 25
1.61×
Q3 25
1.70×
Q2 25
1.69×
Q1 25
1.63×
Q4 24
1.47×
Q3 24
1.50×
Q2 24
1.50×
Q1 24
1.49×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
MDV
MDV
Operating Cash FlowLast quarter
$-22.1M
$15.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
12.34×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
MDV
MDV
Q4 25
$-22.1M
$15.0M
Q3 25
$-31.2M
$4.1M
Q2 25
$-12.1M
$3.9M
Q1 25
$-33.3M
$3.0M
Q4 24
$-17.9M
$18.2M
Q3 24
$-24.1M
$5.1M
Q2 24
$-5.0M
$4.7M
Q1 24
$-18.1M
$3.0M
Free Cash Flow
CCCC
CCCC
MDV
MDV
Q4 25
Q3 25
$-31.6M
Q2 25
Q1 25
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.2M
Q1 24
FCF Margin
CCCC
CCCC
MDV
MDV
Q4 25
Q3 25
-281.5%
Q2 25
Q1 25
Q4 24
-346.5%
Q3 24
-157.2%
Q2 24
-43.1%
Q1 24
Capex Intensity
CCCC
CCCC
MDV
MDV
Q4 25
Q3 25
3.7%
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
0.1%
Q2 24
1.6%
Q1 24
0.0%
Cash Conversion
CCCC
CCCC
MDV
MDV
Q4 25
12.34×
Q3 25
3.95×
Q2 25
Q1 25
3.68×
Q4 24
11.72×
Q3 24
Q2 24
3.55×
Q1 24
0.80×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons